Collegium Pharmaceutical, Inc. has named Barry Duke as executive vice president and chief commercial officer. In addition to Mr. Duke, Mary Ogle joined as vice president of marketing and Timothy Hermes as vice president of government affairs and alliance development.

“Barry’s deep experience, in both small and large organizations make him a great fit to lead our commercial organization as we prepare for FDA approval and launch of Xtampza ER,” said Michael Heffernan, chairman and chief executive officer, Collegium.

Mr. Duke brings twenty-five years of commercial experience in specialty and hospital healthcare markets. Prior to joining Collegium, Mr. Duke was vice president of sales and marketing, U.S. Biosurgery, Sanofi.

Ms. Ogle joined Collegium from Purdue Pharma L.P. where she led all aspects of marketing and managed markets for the company, including the recent launch of Hysingla ER (hydrocodone bitartrate).

Mr. Hermes brings extensive government affairs and alliance development experience to Collegium. His prior experience includes senior government affairs roles at Auxilium Pharmaceuticals and Sepracor.

In addition, Mary Theriault had previously joined Collegium as senior director of commercial operations from Precision Dermatology Inc. and Mark Semiao joined as regional director from Zogenix, Inc. where he launched Zohydro ER.